Advanced Solid Tumor Clinical Trial Landscape

Why advanced solid tumor trial monitoring matters

The "advanced solid tumor" category in ClinicalTrials.gov has become the de facto entry point for novel oncology mechanisms entering the clinic. Phase 1 programs in solid tumors are often the first public signal that a company is advancing a new target — sometimes 12–18 months before any scientific publication or conference presentation.

For pharma business development teams, tracking first-in-human solid tumor registrations is a real-time window into competitive pipeline activity. Key signals to monitor:

• New Phase 1 first-in-human registrations from emerging biotechs — potential licensing targets before Phase 2 data inflates valuations
• Large pharma expanding into novel mechanisms (e.g., Amgen MSI-H, Daiichi Sankyo ADC, Gilead oncology pipeline)
• KRAS/RAS pathway inhibitor programs — the most competitive small molecule space in oncology since 2021
• Next-generation ADC programs targeting novel tumor antigens (GD2, claudin, TROP2 combinations)
• Targeted protein degradation (TPD) — PROTAC and molecular glue programs in early FIH stages
• Tumor-agnostic trials enrolling by biomarker (MSI-H/dMMR, HER2 amplification, NTRK fusion)

Current advanced solid tumor trial activity (as of early 2026)

Based on ClinicalTrials.gov data updated daily by DataLookout:

Over 85% of recruiting advanced solid tumor trials are Phase 1 or Phase 1/2, reflecting the primary use of this classification as a FIH entry point. The industry-sponsored count (31 trials) understates activity — many programs use more specific tumor type designations but are functionally tumor-agnostic.

The advanced solid tumor competitive landscape in 2026

KRAS/RAS pathway inhibitor wave

Following the 2021 approval of sotorasib (Lumakras) and the 2023 approval of adagrasib (Krazati) for KRAS G12C-mutant NSCLC, the competitive landscape for KRAS and broader RAS pathway inhibition has intensified substantially. BridgeBio's oncology unit (TheRas / BBOT) has two simultaneous programs in Phase 1: BBO-10203 in advanced solid tumors and BBO-11818 specifically in KRAS-mutant cancers. Bayer has taken a combination approach, pairing BAY3498264 with approved sotorasib in a Phase 1 study — targeting the combination resistance problem that has limited first-generation KRAS G12C inhibitor durability. For BD teams tracking the RAS pathway, the FIH landscape now includes KRAS G12D inhibitors, pan-RAS approaches, and SOS1 degraders alongside the G12C-specific programs.

ADC programs in solid tumors

Antibody-drug conjugate (ADC) development has accelerated beyond breast cancer and hematology into broad solid tumor settings. Daiichi Sankyo — which has built the leading ADC franchise with trastuzumab deruxtecan (Enhertu) — continues to expand with DS5361b entering Phase 1 in solid tumors. EMD Serono (Merck KGaA) is targeting GD2, a ganglioside antigen expressed in neuroblastoma and multiple solid tumor types, with the ADC M3554. DualityBio, a Chinese biotech with a growing ADC pipeline, has initiated the FIH study of DB-1419. These programs collectively signal a broad hypothesis: that ADC technology can deliver cytotoxic payloads to tumor antigens beyond HER2 and TROP2, potentially expanding ADC utility across a wider range of solid tumor histologies.

Targeted protein degradation (TPD)

Plexium's PLX-61639 is among the newer entrants in the TPD space to enter Phase 1 in solid tumors. Targeted protein degradation — encompassing PROTAC (proteolysis-targeting chimera) and molecular glue degrader approaches — addresses the "undruggable" proteome by recruiting E3 ubiquitin ligases to degrade disease-relevant proteins rather than inhibiting them. The TPD pipeline in oncology has grown rapidly since 2020, and tracking first-in-human registrations in this category provides early visibility into which targets are reaching the clinic. Unlike small molecule inhibitors, degraders offer the possibility of removing proteins that lack catalytic sites for conventional inhibition.

PARP1 selective inhibitors

First-generation PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) are non-selective for PARP1 vs. PARP2, and PARP2 inhibition is associated with hematologic toxicity — anemia, thrombocytopenia — that limits dose intensity and combination potential. Eikon Therapeutics is evaluating IMP1734, a PARP1-selective inhibitor, in Phase 1 with the hypothesis that PARP1 selectivity may preserve PARP trapping efficacy while reducing myelosuppression. If this hypothesis is validated clinically, PARP1-selective agents could enable broader combination use (with checkpoint inhibitors, chemotherapy, or ATR/ATM inhibitors) and potentially recapture indications where first-gen PARP inhibitor benefit was limited by toxicity.

MSI-H/dMMR tumor-agnostic immunotherapy

Amgen has initiated the Phase 1 basket trial of AMG 436 in MSI-H/dMMR solid tumors. Mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) status were the first tumor-agnostic FDA approvals for pembrolizumab (2017) and dostarlimab (2023). New agents targeting this population must demonstrate differentiation from established checkpoint inhibitors — through novel mechanism, combination potential, or activity in pembrolizumab-refractory disease. Tracking new MSI-H/dMMR registrations reveals whether the field views this biomarker-defined population as a viable niche for next-generation immunotherapy strategies.

BeOne Medicines (BeiGene) FIH expansion

BeOne Medicines has registered at least five simultaneous first-in-human solid tumor programs currently recruiting: BG-C9074, BGB-26808, BG-C477, BGB-58067, and BG-75098. This level of concurrent early-stage activity reflects a deliberate strategy of broad mechanism exploration across a diversified oncology pipeline. For competitive intelligence purposes, BeOne's volume of FIH registrations positions them as an emerging player in the early solid tumor space beyond their established approved portfolio (tislelizumab, zanubrutinib).

What we monitor for advanced solid tumor trials

For a broad solid tumor monitoring profile, configure keywords such as:

• Basket/tumor-agnostic: "advanced solid tumor", "metastatic solid tumor", "unresectable solid tumor", "solid tumor adult"
• KRAS/RAS pathway: "KRAS mutant", "KRAS G12C", "KRAS G12D", "KRAS G12V", "pan-RAS", "SOS1"
• Biomarker-driven: "MSI-H", "dMMR", "mismatch repair deficient", "tumor mutational burden", "TMB-high"
• ADC: "antibody drug conjugate", "ADC", "GD2", "TROP2 solid", "HER2 solid tumor"
• TPD: "PROTAC", "molecular glue", "targeted protein degradation", "degrader"

Phase filter: Phase 1 only (for FIH monitoring) or all phases (for broad coverage). Sponsor filter: Industry only for competitive intelligence use cases.

Who uses advanced solid tumor trial monitoring

Pharma business development teams

BD professionals use basket trial registrations as a prospecting tool. A Phase 1 solid tumor program registered today by an emerging biotech may represent a licensing or acquisition target 18–24 months from now — well before Phase 2 data is public. Early visibility enables relationship-building and diligence preparation before competitive pressure drives valuations up.

Oncology-focused investors

Biotech investors in oncology track FIH registrations as leading indicators of pipeline depth and novelty. A company's willingness to file multiple simultaneous Phase 1 programs signals capital confidence and scientific breadth. Tracking new registrations daily across the solid tumor FIH landscape provides a continuously updated view of the early-stage pipeline.

Medical affairs and competitive intelligence teams

Companies with approved solid tumor agents — particularly checkpoint inhibitors, ADCs, and KRAS inhibitors — monitor basket trial registrations to identify emerging threats to market share. A new FIH ADC targeting a shared antigen may not be competitive for 5 years, but understanding the emerging landscape is essential for long-range commercial planning.

Oncology CROs and clinical operations teams

Contract research organizations track new Phase 1 solid tumor registrations to identify sponsors entering clinical development — prospective clients for trial management, site selection, and patient recruitment services. The volume of concurrent FIH programs in solid tumors represents a substantial addressable market for specialized oncology CROs.

Frequently asked questions